Agomab Therapeutics Director David R. Epstein Reports $103,500 Common Share Acquisition

Bitget2026/11/06 11:39

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Agomab Therapeutics director David R. Epstein purchased 15,000 common shares, raising his direct holdings to 40,000 shares.
Purchases comprised 5,000 shares each at $6.81, $6.91 and $6.98 per share.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agomab Therapeutics NV published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001445826-26-000018), on November 06, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Agomab Therapeutics Director David R. Epstein Reports $103,500 Common Share Acquisition

You may also like

Crypto prices